Oramed Pharmaceuticals (ORMP) Net Cash Flow (2010 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Net Cash Flow came in at -$32.8 million in Q1 2026, down 263.04% YoY from $20.1 million in Q1 2025, and down 432.02% on a QoQ basis from -$6.2 million in Q4 2025.
Oramed Pharmaceuticals (ORMP) Net Cash Flow (2010 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 17 years of Net Cash Flow data on file, last reported at -$32.8 million in Q1 2026.
- Quarterly Net Cash Flow fell 263.04% year-over-year to -$32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$60.9 million (down 208.92% YoY) and the FY2025 annual result came in at -$8.4 million, down 118.61% from the prior year.
- Net Cash Flow eased to -$32.8 million in Q1 2026, from -$6.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $66.2 million in Q2 2024 to a low of -$58.4 million in Q2 2025.
- A 5-year average of -$809000.0 and a median of $1.9 million in 2022 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 481.58% in 2024, down 3263.72% in 2024.
- Tracing ORMP's Net Cash Flow over 5 years: stood at $7.4 million in 2022, then tumbled by 51.46% to $3.6 million in 2023, then surged by 244.17% to $12.3 million in 2024, then slumped by 150.0% to -$6.2 million in 2025, then plunged by 432.02% to -$32.8 million in 2026.
- The last three Net Cash Flow figures came in at -$32.8 million (Q1 2026), -$6.2 million (Q4 2025), and $36.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 225.59 Mn |
| 10 | Oramed Pharmaceuticals | 198.64 Mn | 198.64 Mn | - | 2.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.16 Mn |
| Jun 30, 2026 | 2.16 Mn |
| Mar 31, 2026 | -32.77 Mn |
| Mar 31, 2026 | -32.77 Mn |
| Dec 31, 2025 | -6.16 Mn |
| Dec 31, 2025 | -6.16 Mn |
| Sep 30, 2025 | 36.38 Mn |
| Sep 30, 2025 | 36.38 Mn |
| Jun 30, 2025 | -58.39 Mn |
| Jun 30, 2025 | -58.39 Mn |
| Mar 31, 2025 | 20.10 Mn |
| Mar 31, 2025 | 20.10 Mn |
| Dec 31, 2024 | 12.32 Mn |
| Dec 31, 2024 | 12.32 Mn |
| Sep 30, 2024 | -42.65 Mn |
| Sep 30, 2024 | -42.65 Mn |
| Jun 30, 2024 | 66.18 Mn |
| Jun 30, 2024 | 66.18 Mn |
| Mar 31, 2024 | 9.52 Mn |
| Mar 31, 2024 | 9.52 Mn |